Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma - Test2 - elhamkhani - TriplyDB

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

http://www.wikidata.org/entity/Q30371806

about

Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib Novel agents in the treatment of multiple myeloma: a review about the future Role of the tumor microenvironment in mature B-cell lymphoid malignancies Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Ibrutinib Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy Lymphoma Immunotherapy: Current Status Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms Myeloid Cells as Targets for Therapy in Solid Tumors Predictive biomarkers in precision medicine and drug development against lung cancer Targeting the B-cell receptor signaling pathway in B lymphoid malignancies Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors Risk factors for etiology and prognosis of mantle cell lymphoma Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib Management of mantle cell lymphoma in the elderly patient High-dimensional single-cell cancer biology Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review AACR Cancer Progress Report 2014 Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Second-generation inhibitors of Bruton tyrosine kinase Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors Secondary mutations as mediators of resistance to targeted therapy in leukemia Targets for Ibrutinib Beyond B Cell Malignancies Mantle cell lymphoma: observation to transplantation Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells The European Hematology Association Roadmap for European Hematology Research: a consensus document Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.Pseudokinases: update on their functions and evaluation as new drug targets.

P2860

Q26738946-49371A64-DB7B-41B3-8CAA-62D7D0BEC922 Q26744277-B34FA44F-3EBF-4F81-A882-DD089D9468F8 Q26745924-1C1C89D4-927E-4D23-A7B1-E1E22BAD0F47 Q26748775-46CDDC29-337D-4D81-AF0F-D7025DDFF12D Q26749010-4D2FE350-7FF3-4109-A930-16AFB2B04118 Q26749139-A8A14F9C-C64F-45FA-8BF7-2FA574DF7837 Q26772907-73EC22B4-DE07-491F-804A-9243FFB7A61F Q26773236-46D228D5-F55D-468C-8F7D-535F762357D3 Q26782270-A6ED571D-3E4A-48BE-9EC4-F6B00D02B661 Q26782902-09E74A49-7645-4DD0-8213-3BBDDC639CE4 Q26783430-71397375-4775-41B8-ADE4-CFAF039FFD29 Q26784108-2FBB14F9-6766-46E4-907C-764D1AA53BA6 Q26795594-6606A02C-4619-48CD-8441-A19369351075 Q26801832-E1B7DF38-85E6-4A68-893B-008F10191C26 Q26824536-41500F60-D7AD-4CE6-BB84-33FAF424CD14 Q26828782-D1AE147A-E171-4321-BD45-356421481FC3 Q26851417-91DAA877-D102-4763-A822-55CEF80238C1 Q26858960-949EAF05-70EB-4175-84A8-0E2FCBF6AA1B Q26991890-0BEE84ED-584D-4E78-B1C8-810E0843F19C Q26995113-1B68BEED-2DF1-41D1-AB9A-24D3AD47334D Q26999395-5C5CDC15-25CB-4168-8647-1DEB19894893 Q27021173-8567B872-D0A8-4FF5-9514-B740EA5D4703 Q27025812-E9F40E11-852C-498F-B196-F22EB72455F8 Q27026912-9D0BB901-0662-4F5B-9348-B3F9A7823C42 Q27304386-C1A454A6-8270-4B93-A59C-981817F9C25A Q27346723-6CA50BCE-B2C4-4EDB-9AD1-1F684C5ABFD5 Q28066316-0B37A9EF-FD92-45F6-9117-009695AF8566 Q28070090-399647BB-5216-4512-9750-BD0AEE583254 Q28075606-DF84403E-FEEF-432C-8B30-CA67D696664B Q28076118-49470A99-A347-4895-AB10-B6BA306F5DAA Q28081162-FABA0947-24A1-4908-86CD-3F30132443B0 Q28087213-ED4F1C7D-872E-47DC-88BF-5E1A47303877 Q28087772-0572365E-9F5C-4682-8FDE-8AD8DF8FBCDD Q28256317-D1B8D570-8709-4408-98C4-9C2FE0D3A8DD Q28547322-19180852-74F8-43A9-AE5A-FA321AB0E110 Q28830861-21740798-9ECE-46A6-815F-97CDE28B5F10 Q30279207-9CE46656-110C-4F9C-9533-2DC5455F506F Q30303054-9822B65B-9CF0-403B-943D-95D9952711E5 Q30395557-ED7E248A-E3B3-4DE5-ABD1-76C1B32605F0 Q30397636-DABB6BDE-9CBC-4014-A6BE-28E8460BD10E

P2860

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

http://www.wikidata.org/entity/Q30371806

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

@ast

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

@en

type

label

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

@ast

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

@en

prefLabel

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

@ast

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

@en

P1433

Q30371806-F730C6FB-F168-4C21-AC16-949948EB18F2

P1476

Q30371806-506A2C99-805F-4217-B6F5-45DBB9C5E59D

P2093

Q30371806-0C3BD2BA-9F75-4E33-9D46-57A200B555DC

Q30371806-0DBA0E07-6FD9-4F1C-B66E-93739499FCE5

Q30371806-14172B8F-4447-4B51-8AB5-E86D5D1C6D3D

Q30371806-15D6D4D6-D1B6-4E0F-9B0A-807C57CA1BC9

Q30371806-1A4AE559-552A-4460-BA22-0A730225041C

Q30371806-226F37ED-1103-44B3-BF1C-DBC37536CE2D

Q30371806-25C945BC-723B-44A5-88EF-69BA576490BA

Q30371806-2B4C6132-48F0-48F0-AA83-1F68D654EC0C

Q30371806-2D047F5F-7502-4072-93F9-A53404DF32C1

Q30371806-339DA8BB-2C9E-426B-8161-D62CA6D06C9D

P2860

Q30371806-101C1FC3-4A63-40B9-9A05-DAA319DA5EBC

Q30371806-216CCA8C-5920-4F8F-9414-389005D3514A

Q30371806-2A7475F1-713D-4790-98B7-448912D6E4BC

Q30371806-30982C2F-A9CB-4AE8-9470-DB2DA252A4E7

Q30371806-4AA06115-4E0F-48EE-943D-673645C0D6D2

Q30371806-524215A2-82BB-4A1D-B4FE-3255459C8651

Q30371806-529A860D-D937-4CF6-AA24-EA3F08CE4F3A

Q30371806-59794532-D7AD-4CEF-8019-7B208072C869

Q30371806-5A8DD063-4F24-4D63-A4E2-E598D4B484C1

Q30371806-70590171-5462-46D9-A04F-5D6FF8317AF8

P304

Q30371806-8574AD18-354C-4BA5-8D92-9E0B1C27362C

P31

Q30371806-1AC0405F-C4A9-4908-AEB7-8B114E6463F6

P356

Q30371806-C5C7F84E-B694-4AF5-815F-B2AAD1517F7D

P407

Q30371806-9AB0D028-6840-4C52-BDF9-81EB31AE9EB3

P433

Q30371806-06AC08C1-92EC-4FA5-A28E-7BD402E8708F

P478

Q30371806-45F6D06A-80D8-4FE4-AF76-EB290C38F763

P50

Q30371806-6D539199-DB55-4D40-AE1F-F07172C93984

Q30371806-7F980DD4-F6BC-427F-8BB0-A8C7D628218C

Q30371806-947E6BB4-E748-42EC-AE4C-C58F8491E8A9

Q30371806-A8B00B62-9B04-4CEE-B198-8A02CC37366A

P577

Q30371806-B509E650-4A59-4FC9-9163-246FDD62C918

P5875

Q30371806-57EFABE1-9E2F-4D82-BC5F-8C5D16945AF1

P698

Q30371806-66B1C1B5-08FC-448A-81F0-0E907AF4C502

P932

Q30371806-C768324F-84BC-463C-AE05-4AE0AA5399F5

P356

P1433

The New England Journal of Medicine

P1476

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

@en

P2093

Andre Goy

http://www.w3.org/2001/XMLSchema#string

Betty Y Chang

http://www.w3.org/2001/XMLSchema#string

Bingliang Fang

http://www.w3.org/2001/XMLSchema#string

Brad S Kahl

http://www.w3.org/2001/XMLSchema#string

Darrin M Beaupre

http://www.w3.org/2001/XMLSchema#string

Ewa Chmielowska

http://www.w3.org/2001/XMLSchema#string

Fong Clow

http://www.w3.org/2001/XMLSchema#string

Jesse McGreivy

http://www.w3.org/2001/XMLSchema#string

Jorge E Romaguera

http://www.w3.org/2001/XMLSchema#string

Joseph J Buggy

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

P304

507-516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1306220

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Jacqueline Barrientos

Stephan Stilgenbauer

Wojciech Jurczak

P577

2013-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

239940905

http://www.w3.org/2001/XMLSchema#string

P698

23782157

http://www.w3.org/2001/XMLSchema#string

P932

4513941

http://www.w3.org/2001/XMLSchema#string